Related Experiment Video
Updated: Sep 24, 2025
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
CBX7 represses the POU2F2 to inhibit the PD-L1 expression and regulate the immune response in bladder cancer
Weigang Ren1, Jiannan Ren2, Naiwen Zhang3
1Department of Urology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, 410005, China.
Abstract:
Bladder cancer (BC) is one of the most common malignant tumors of the urinary system worldwide. To date, immune checkpoint inhibitors (including PD-1/PD-L1) have been applied to treat patients with bladder cancer in the clinic and achieved the promising outcome. Further improvement of the anticancer efficiency of these immune therapies is crucial for bladder cancer. Our previous RNA-seq data on CBX7 (GSE185630) suggested that CBX7 might repress PD-L1 expression and PD-1 checkpoint pathway in cancer. In this study, we revealed that CBX7 downregulated the expression of POU2F2 that indirectly repressed the PD-L1 in BC cells. Depletion of CBX7 resulted in resistance to PD-1 blockade in bladder cancer. Collectively, our results suggested that the CBX7/POU2F2/PD-L1 axis plays an important role in determining the antitumor effect of PD-1 blockade in bladder cancer.
Insights
CBX7 represses PD-L1 expression in bladder cancer by downregulating POU2F2. CBX7 depletion causes resistance to PD-1 blockade, highlighting the CBX7/POU2F2/PD-L1 axis for improving immunotherapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Bladder cancer (BC) is a prevalent malignancy globally.
- Immune checkpoint inhibitors targeting PD-1/PD-L1 show promise in BC treatment.
- Enhancing BC immunotherapy efficacy remains a critical challenge.
Purpose of the Study:
- To investigate the role of CBX7 in regulating PD-L1 expression and PD-1 blockade response in bladder cancer.
- To elucidate the molecular mechanism by which CBX7 influences PD-L1 expression.
Main Methods:
- RNA sequencing (RNA-seq) data analysis (GSE185630).
- Experimental manipulation of CBX7 expression in bladder cancer cells.
- Assessment of PD-L1 expression and response to PD-1 blockade.
Main Results:
- CBX7 was found to downregulate POU2F2 expression, which indirectly represses PD-L1.
- Depletion of CBX7 led to resistance to PD-1 blockade in bladder cancer models.
- The CBX7/POU2F2/PD-L1 pathway was identified as a key regulator.
Conclusions:
- The CBX7/POU2F2/PD-L1 axis is crucial for determining the efficacy of PD-1 blockade in bladder cancer.
- Targeting this axis may offer novel strategies to overcome immunotherapy resistance.
- CBX7's role in modulating the tumor immune microenvironment warrants further investigation.
